Lu S - Search Results

1

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.

Zhou Q, Xu CR, Cheng Y, Liu YP, Chen GY, Cui JW, Yang N, Song Y, Li XL, Lu S, Zhou JY, Ma ZY, Yu SY, Huang C, Shu YQ, Wang Z, Yang JJ, Tu HY, Zhong WZ, Wu YL. Zhou Q, et al. Among authors: lu s. Cancer Cell. 2021 Sep 13;39(9):1279-1291.e3. doi: 10.1016/j.ccell.2021.07.005. Epub 2021 Aug 12. Cancer Cell. 2021. PMID: 34388377 Free article. Clinical Trial.

2

[Comparison of single-agent docetaxel versus docetaxel plus platinum combination agent in second-line treatment for advanced non-small cell lung cancer].

Zhang YF, Yu YF, Lu S. Zhang YF, et al. Among authors: lu s. Zhonghua Yi Xue Za Zhi. 2009 Jun 9;89(22):1544-8. Zhonghua Yi Xue Za Zhi. 2009. PMID: 19953882 Chinese.

3

Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.

Zhang YF, Chen ZW, Lu S. Zhang YF, et al. Among authors: lu s. Chin Med J (Engl). 2009 Oct 20;122(20):2472-6. Chin Med J (Engl). 2009. PMID: 20079162

4

[Safety analysis of ambulatory chemotherapy in lung cancer].

Feng Y, Lu S, Song Z, Xu L, Shi Y, Chen Z. Feng Y, et al. Among authors: lu s. Zhongguo Fei Ai Za Zhi. 2010 Jul;13(7):713-6. doi: 10.3779/j.issn.1009-3419.2010.07.10. Zhongguo Fei Ai Za Zhi. 2010. PMID: 20673488 Free PMC article. Chinese.

5

A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.

Yu YF, Chen ZW, Zhou Z, Song ZB, Li ZM, Jian H, Zhang YF, Lu S. Yu YF, et al. Among authors: lu s. Chemotherapy. 2010;56(6):472-7. doi: 10.1159/000321016. Epub 2010 Nov 23. Chemotherapy. 2010. PMID: 21099219

6

Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients.

Song Z, Yu Y, Chen Z, Lu S. Song Z, et al. Among authors: lu s. Med Oncol. 2011 Dec;28 Suppl 1:S605-12. doi: 10.1007/s12032-010-9753-3. Epub 2010 Nov 30. Med Oncol. 2011. PMID: 21116876

7

Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment.

Song ZB, Yu YF, Chen ZW, Lu S. Song ZB, et al. Among authors: lu s. Chin Med J (Engl). 2011 Aug;124(15):2279-83. Chin Med J (Engl). 2011. PMID: 21933557

8

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.

Zhang L, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Zhang X, Hayashi N, Wang M; INFORM investigators. Zhang L, et al. Among authors: lu s. Lancet Oncol. 2012 May;13(5):466-75. doi: 10.1016/S1470-2045(12)70117-1. Epub 2012 Apr 17. Lancet Oncol. 2012. PMID: 22512843 Clinical Trial.

9

[Efficacy of gemcitabine and vinorelbine in first-line treatment with advanced non-small cell lung cancer: a multicentre retrospective study].

Yu Y, Zhang L, Ren Z, Zhao J, Li Z, Lu S. Yu Y, et al. Among authors: lu s. Zhongguo Fei Ai Za Zhi. 2012 May;15(5):281-6. doi: 10.3779/j.issn.1009-3419.2012.05.06. Zhongguo Fei Ai Za Zhi. 2012. PMID: 22613334 Free PMC article. Chinese.

10

The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.

Shen L, Li Z, Shen S, Niu X, Yu Y, Li Z, Liao M, Chen Z, Lu S. Shen L, et al. Among authors: lu s. Lung Cancer. 2012 Dec;78(3):193-200. doi: 10.1016/j.lungcan.2012.08.012. Epub 2012 Sep 15. Lung Cancer. 2012. PMID: 22985911

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17,022 results

Search Page

Filters